Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Lurbinectedin (Primary) ; Olaparib (Primary)
- Indications Breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms POLA
- 21 Jun 2017 Planned End Date changed from 1 Jul 2018 to 1 Oct 2019.
- 21 Jun 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jul 2019.
- 06 Jun 2017 Results (n=20) of phase I of the study assessing tolerability,pharmacokinetics and pharmacodynamics presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History